231 related articles for article (PubMed ID: 10840432)
1. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
2. Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era.
Shahabi A; Satkunasivam R; Gill IS; Lieskovsky G; Daneshmand S; Pinski JK; Stern MC
Can Urol Assoc J; 2016; 10(1-2):E17-22. PubMed ID: 26858782
[TBL] [Abstract][Full Text] [Related]
3. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.
Morgan TM; Lange PH; Porter MP; Lin DW; Ellis WJ; Gallaher IS; Vessella RL
Clin Cancer Res; 2009 Jan; 15(2):677-83. PubMed ID: 19147774
[TBL] [Abstract][Full Text] [Related]
4. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.
Bjartell AS; Al-Ahmadie H; Serio AM; Eastham JA; Eggener SE; Fine SW; Udby L; Gerald WL; Vickers AJ; Lilja H; Reuter VE; Scardino PT
Clin Cancer Res; 2007 Jul; 13(14):4130-8. PubMed ID: 17634540
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer?
Boxler S; Djonov V; Kessler TM; Hlushchuk R; Bachmann LM; Held U; Markwalder R; Thalmann GN
Am J Pathol; 2010 Nov; 177(5):2216-24. PubMed ID: 20889560
[TBL] [Abstract][Full Text] [Related]
6. Serum methionine metabolites are risk factors for metastatic prostate cancer progression.
Stabler S; Koyama T; Zhao Z; Martinez-Ferrer M; Allen RH; Luka Z; Loukachevitch LV; Clark PE; Wagner C; Bhowmick NA
PLoS One; 2011; 6(8):e22486. PubMed ID: 21853037
[TBL] [Abstract][Full Text] [Related]
7. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy.
Hoey C; Ahmed M; Fotouhi Ghiam A; Vesprini D; Huang X; Commisso K; Commisso A; Ray J; Fokas E; Loblaw DA; He HH; Liu SK
J Transl Med; 2019 May; 17(1):173. PubMed ID: 31122242
[TBL] [Abstract][Full Text] [Related]
8. The long-term outcomes of radical prostatectomy for very high-risk prostate cancer pT3b-T4 N0-1 on definitive histopathology.
Kliment J; Elias B; Baluchova K; Kliment J
Cent European J Urol; 2017; 70(1):13-19. PubMed ID: 28461982
[TBL] [Abstract][Full Text] [Related]
9. Outcome of surgery in locally advanced pT3a prostate cancer.
Milonas D; Baltrimavicius R; Grybas A; Gudinaviciene I; Trumbeckas D; Kincius M; Auskalnis S; Jievaltas M
Cent European J Urol; 2011; 64(4):209-12. PubMed ID: 24578895
[TBL] [Abstract][Full Text] [Related]
10. A Chance Finding of High Grade Prostate Cancer in a 35-Year-Old Male - A Case Report and Outcomes of Robotic Radical Prostatectomy in Young Men with Prostate Cancer.
Virk A; Treacy PJ; Zhong W; Doeuk N; Doeuk C; Leslie S
Res Rep Urol; 2023; 15():571-576. PubMed ID: 38145158
[TBL] [Abstract][Full Text] [Related]
11. Laparoscopic radical prostatectomy: Oncological outcome analysis from a single-center Indian experience of 6 years.
Mishra S; Agrawal V; Khatri N; Sharma R; Kurien A; Ganpule A; Muthu V; Sabnis RB; Desai MR
Indian J Urol; 2012 Jan; 28(1):32-6. PubMed ID: 22557714
[TBL] [Abstract][Full Text] [Related]
12. Lymphovascular Invasion at the Time of Radical Prostatectomy Adversely Impacts Oncological Outcomes.
Sathianathen NJ; Furrer MA; Mulholland CJ; Katsios A; Soliman C; Lawrentschuk N; Peters JS; Zargar H; Costello AJ; Hovens CM; Bishop C; Rao R; Tong R; Steiner D; Moon D; Thomas BC; Dundee P; Calero JAR; Thalmann GN; Corcoran NM
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201549
[TBL] [Abstract][Full Text] [Related]
13. Comorbidity and survival of patients selected for radical prostatectomy at an age of 75 years or older.
Froehner M; Koch R; Wirth MP
Asian J Androl; 2013 Sep; 15(5):667-71. PubMed ID: 23728589
[TBL] [Abstract][Full Text] [Related]
14. Oncologic outcomes of surgery in t3 prostate cancer: experience of a single tertiary center.
Milonas D; Smailyte G; Jievaltas M
Adv Urol; 2012; 2012():164263. PubMed ID: 22216025
[TBL] [Abstract][Full Text] [Related]
15. The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer.
Sung D; Schmidt B; Tward JD
Clin Genitourin Cancer; 2024 Apr; 22(2):426-433.e5. PubMed ID: 38290900
[TBL] [Abstract][Full Text] [Related]
16. Management of clinically localized prostate cancer.
Lepor H
Rev Urol; 2004; 6 Suppl 2(Suppl 2):S3-S12. PubMed ID: 16985859
[TBL] [Abstract][Full Text] [Related]
17. The wisdom of the commons: ensemble tree classifiers for prostate cancer prognosis.
Koziol JA; Feng AC; Jia Z; Wang Y; Goodison S; McClelland M; Mercola D
Bioinformatics; 2009 Jan; 25(1):54-60. PubMed ID: 18628288
[TBL] [Abstract][Full Text] [Related]
18. Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy.
Velho PI; Lim D; Wang H; Park JC; Kaur HB; Almutairi F; Carducci MA; Denmeade SR; Markowski MC; Isaacs WB; Antonarakis ES; Pritchard CC; Eisenberger MA; Lotan TL
JCO Precis Oncol; 2019; 3():. PubMed ID: 31650100
[TBL] [Abstract][Full Text] [Related]
19. Histologically Overt Stromal Response and the Risk of Progression after Radical Prostatectomy for Prostate Cancer.
Sayan M; Tuac Y; Kucukcolak S; Rowan MD; Pratt GK; Aktan C; Tjio E; Akbulut D; Moningi S; Leeman JE; Orio PF; Nguyen PL; D'Amico AV; Akgul M
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791950
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
